PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Related Keywords

Australia ,Melbourne ,Victoria ,San Francisco ,California ,United States ,Australian ,Russell Tait ,Michael Coote ,Prezia Sustained Drug Delivery Technology ,Prnewswire Polyactiva Pty Ltd ,Horizons Forum ,Activa Pty Ltd ,Primary Open Angle Glaucoma ,Chief Executive Officer ,Annual Glaucoma ,Associate Professor Michael Coote ,Melbourne Eye Specialists ,Technology ,Health ,Business ,Glaucoma ,Pr Newswire ,